Navigation Links
Congress Sets New Course for Lung Cancer Research; Approves $20 Million for New Defense Department Program
Date:9/27/2008

WASHINGTON, Sept. 27 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) announced today that Congress approved $20 million for a new lung cancer research program at the Department of Defense (DOD) -- a top LCA priority.

The president is expected to sign the bill containing the new lung cancer research program and the funding will be available in fiscal year 2009 which begins October 1.

"This is our top priority; this is the turning point. It is a breakthrough that lung cancer patients, their families and caregivers have been waiting for," said Laurie Fenton-Ambrose, LCA President & CEO. "By setting up this new program, Congress is finally acknowledging that the situation is urgent and that more research must be focused on lung cancer which is causing more deaths each year than breast, prostate and colon cancers combined."

Over 215,000 people will be diagnosed with lung cancer in the United States in 2008 and the majority will die in less than a year.

The new program, entitled the Peer Reviewed Lung Cancer Research Program, will be administered and funded by the DOD.

Former Transportation Secretary Norman Y. Mineta, a member of the LCA Board of Directors and a lung cancer survivor, said that DOD is "mission-oriented" and that the department's vast experience with cutting edge technology will accelerate improvements in the detection, diagnosis and treatment of lung cancer.

Congress started funding cancer research programs through DOD in the mid-nineties with a $25 million appropriation for breast cancer. Over the years a number of research programs have been added for other cancers, but not lung cancer -- until this breakthrough.

Fenton-Ambrose praised Congressman John P. Murtha (D-PA) and Senator Daniel K. Inouye (D-HI) for their leadership and commitment on the issue.

The legislation specifically notes that lung cancer is the most lethal of all cancers, taking more lives each year than all other major
'/>"/>

SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Updated MD-CARE Act Receives Final Congressional Approval
2. AVMA Addresses Livestock Health Issues Before U.S. Congress
3. Lilly to Sponsor Congressional Black Caucus Foundations Annual Legislative Conference
4. ADA Asks Congress to Strengthen Medicaid Oral Health Programs
5. Pro-Life Chair to Congress: We Cant Reduce Abortions By Promoting Abortion
6. Testifying Before Congress, Trust for Americas Health Urges FDA Spending Cap Until Realistic Budget Request is Made
7. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
8. Statement From the Office of Congresswoman Stephanie Tubbs Jones
9. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
10. 1st World Congress On Interventional Therapies for Type 2 Diabetes
11. Pelosi Statement on Congress Sending Consumer Product Safety Legislation to President
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Folk Medicine Therapy May Prevent Alcoholic Relapse 54302 1Folk Medicine Therapy May Prevent Alcoholic Relapse 54302 2Beckman Coulter Announces the Creation of Beckman Coulter Genomics 54297 1Beckman Coulter Announces the Creation of Beckman Coulter Genomics 54297 2Beckman Coulter Announces the Creation of Beckman Coulter Genomics 54297 3Biostar Pharmaceuticals Inc to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday August 14 2009 at 10 3A30 a m EDT 13519 1Biostar Pharmaceuticals Inc to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday August 14 2009 at 10 3A30 a m EDT 13519 2Biostar Pharmaceuticals Inc to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday August 14 2009 at 10 3A30 a m EDT 13519 3